接受一线ALK抑制剂治疗的ALK阳性肺癌新诊断脑转移患者放疗的真实世界应用
这项回顾性、观察性、真实世界模式照护研究利用全国性电子健康记录去标识纵向数据库,纳入2014年1月1日至2019年8月31日期间一线ALK抑制剂单药治疗的ALK阳性晚期NSCLC伴脑转移患者随机样本。352例纳入患者中146例有脑转移,104例接受中枢神经系统定向局部治疗、42例未接受,接受放疗者中89.4%为单纯放疗。多变量分析显示2017年及以后首次出现脑转移者接受脑转移局部治疗率较2017年前降低(调整发病率比0.63,95%CI 0.41-0.95,P=0.026),而全脑放疗比例无变化(调整发病率比0.70,95%CI 0.24-2.06,P=0.517)。
要点
- 352例纳入患者中146例有脑转移,104例接受中枢神经系统定向局部治疗,42例未接受。
- 接受放疗者中单纯立体定向放射外科最常见(53%),其次为单纯全脑放疗(39%)。
- 2017年及以后首次脑转移者局部治疗率较之前降低(调整发病率比0.63,95%CI 0.41-0.95)。
核心结论
- 在接受一线ALK抑制剂治疗的NSCLC新发脑转移患者中,中枢神经系统定向放疗的使用呈下降趋势。
- 作者指出这些患者的临床结局需要持续研究,因为医生可能越来越倾向于推迟脑转移的 upfront 局部治疗,转而使用中枢神经系统活性改善的新型靶向药物。
研究设计与样本
- 回顾性、观察性、真实世界模式照护研究,使用全国性电子健康记录去标识纵向数据库。
- 纳入2014年1月1日至2019年8月31日期间一线ALK抑制剂单药治疗的ALK阳性晚期NSCLC伴脑转移患者随机样本。
- 以首次脑转移为索引日期,结局为4个月内脑定向局部治疗,采用多变量改良Poisson回归(稳健误差方差)检验趋势,含2017年及以后指示变量(阿来替尼获批)。
- 共纳入352例患者,其中146例有脑转移。
主要发现
- 146例有脑转移患者中,104例接受中枢神经系统定向局部治疗,42例未接受。
- 接受放疗者中89.4%为单纯放疗,单纯立体定向放射外科最常见(53%),其次为单纯全脑放疗(39%)。
- 2017年及以后首次脑转移者接受脑转移局部治疗率较2017年前降低(调整发病率比0.63,95%CI 0.41-0.95,P=0.026)。
- 2017年及以后全脑放疗治疗脑转移的比例较之前无显著变化(调整发病率比0.70,95%CI 0.24-2.06,P=0.517)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Management paradigms now allow for systemic targeted drugs before central nervous system (CNS)-directed radiation therapy (RT) in selected asymptomatic patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). We aimed to quantify how novel targeted agents with improved CNS activity, such as second-generation anaplastic lymphoma kinase (ALK) inhibitors (eg, alectinib), might affect the role of CNS-directed RT. METHODS AND MATERIALS: This retrospective, observational, real-world, patterns-of-care study used a nationwide, electronic, health record-derived, de-identified, longitudinal database. A random sample of patients with ALK+ advanced NSCLC and BM on first-line ALK-inhibitor monotherapy between January 1, 2014 and August 31, 2019 were included. Using an index date of the first instance of BM, the outcome was brain-directed local treatment within 4 months. Trends over time were reported and tested using multivariable modified Poisson regression with robust error variance, including an indicator during or after 2017 (when alectinib was approved). RESULTS: Of the 352 included patients, 146 had BM. In addition, 104 patients received CNS-directed local therapy, and 42 did not. The majority of patients (89.4%) were treated with RT alone. Of those receiving RT, stereotactic radiosurgery monotherapy was the most common (53%), followed by whole brain RT alone (39%). On multivariable analysis, patients who had their first BM during or after 2017 had a decreased rate of receiving local BM treatment versus those before 2017 with an adjusted incidence rate ratio of 0.63 (95% confidence interval [CI], 0.41-0.95; P = .026). We found no change in the proportion of BM treated with whole brain RT during or after 2017 versus before (adjusted incidence rate ratio: 0.70; 95% CI: 0.24-2.06; P = .517). CONCLUSIONS: We found decreasing use of CNS-directed RT in patients with NSCLC with new BM on first-line ALK inhibitors. Clinical outcomes for these patients require continued investigation, because physicians may become increasingly comfortable deferring upfront local therapy for BM in lieu of novel targeted agents with improved CNS activity.
引用
- Kumar S, Wang X, Pittell H, et al. Real-world Use of Radiation for Newly Diagnosed Brain Metastases in Patients With ALK-positive Lung Cancer Receiving First-line ALK Inhibitor. Int J Radiat Oncol Biol Phys. 2022. PMID: 35870711. doi:10.1016/j.ijrobp.2022.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。